Home
    Disclaimer
    ← Back to DOET
    DOET molecular structure

    DOET Stats & Data

    Psychedelic Stimulant Research-chemical
    Doe Dmea Hecate
    Chemical Class Amphetamine
    Psychoactive Class Psychedelic / Stimulant
    Half-Life Human half-life unknown; rodent/published estimates for related DOx suggest multi-hour elimination with prolonged subjective effects.

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (partial)
    5-HT2B receptor agonist (partial)
    5-HT2C receptor agonist (partial)

    History & Culture

    1963–1967

    DOET was discovered by Alexander Shulgin during the 1960s while he was employed at Dow Chemical Company. Following his synthesis of the structurally related compound DOM in 1963 and the subsequent recognition of its psychoactive properties in 1964, Shulgin began systematically assessing similar analogues. During this investigation, he found that DOET possessed distinctive characteristics as what he termed a "psychic energizer" when administered at low doses—producing cognitive enhancement without the pronounced sensory distortions associated with higher doses or other psychedelics. Recognizing its potential as a pharmaceutical agent, Shulgin proposed DOET to Dow Chemical Company for development. The company found the compound sufficiently promising to advance it toward clinical investigation, commissioning neuroscientist Solomon H. Snyder at Johns Hopkins University to conduct formal human studies. However, this development pathway was abruptly terminated in 1967 when DOM emerged as a street drug in San Francisco under the name "STP." The public health crisis that ensued—precipitated by psychedelic chemist Owsley Stanley distributing very-high-dose DOM tablets after learning of the compound from Shulgin—prompted Dow Chemical Company to withdraw entirely from research on DOET and related compounds.

    1968–1974

    Despite the termination of Dow's research program, Solomon Snyder continued investigating DOET through academic channels. In 1968, he and his colleagues published the first formal description of the compound in the scientific literature. Snyder remained interested in DOET's potential therapeutic applications, particularly its ability to produce cognitive enhancement at sub-psychedelic doses. Between 1968 and 1974, Snyder conducted and published three clinical trials examining low-dose DOET in human subjects. These studies explored the compound's effects at dosage levels that enhanced cognition without producing overt psychedelic manifestations. Despite this sustained research effort demonstrating its properties, DOET was never further developed as a pharmaceutical medication.

    DOET has carried several designations throughout its history. Alexander Shulgin originally named the compound DOE, following the standard naming convention of the DOx series. However, he subsequently recognized that "DOE" was also an established acronym for desoxyephedrine (methamphetamine), creating potential confusion in the literature. To address this ambiguity, he revised the name to DOET (sometimes written DOEt), incorporating the complete "ethyl" designation to clearly distinguish it from other substances. Beyond its systematic nomenclature, Shulgin also designated the compound Hecate after the Greek goddess, placing it among the substances he classified as the "Classic Ladies" in his writings. The abbreviation DMEA, derived from dimethoxyethylamphetamine, represents another alternative name that has appeared in reference to this compound.

    Effect Profile

    Curated + 2 Reports
    Psychedelic 3.1

    Mild visuals with low body load and headspace

    Visual Intensity×3
    4
    Headspace Depth×3
    2
    Auditory Effects×1
    0
    Body Load / Somatic Effects×1
    3
    Stimulant 2.6

    Strong anxiety/jitters with moderate euphoria, low stimulation

    Stimulation / Energy×3
    3
    Euphoria / Mood Lift×2
    6
    Focus / Productivity×2
    0
    Anxiety / Jitters×1
    10
    Based on reports from:
    PiHKAL PiHKAL #66: DOET Erowid Experience Reports PsychonautWiki DOET

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Human half-life unknown; rodent/published estimates for related DOx suggest multi-hour elimination with prolonged subjective effects.
    Addiction Potential
    Low; classic serotonergic psychedelics typically show minimal reinforcement or compulsive use.

    Tolerance Decay

    Full tolerance 1d Half tolerance 5d Baseline ~10d

    Tolerance to 5‑HT2A agonists develops quickly and decays over 1–2 weeks; cross‑tolerance across serotonergic psychedelics is expected. Data are inferred from human/animal LSD literature and community experience; specific DOET kinetics are sparsely characterized.

    Cross-Tolerances

    LSD
    70% ●●○
    Psilocybin
    60% ●○○
    Other DOx psychedelics
    80% ●●○

    Experience Report Analysis

    Erowid
    2 Reports
    2000–2015 Date Range
    1 With Age Data

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Form / Preparation

    Most common forms and preparations reported

    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    United States Not specifically scheduled (Analogue Act may apply) DOET is not explicitly listed as a controlled substance and has not been specifically scheduled by federal drug enforcement agencies. However, the Controlled Substance Analogue Enforcement Act of 1986 may apply when the substance is intended for human consumption, as DOET is a close structural analogue of DOM (Schedule I). This could potentially subject possession or distribution to Schedule I penalties depending on prosecutorial interpretation and intent of use.

    Harm Reduction

    drugs.wiki

    - Potency lies in the low milligram range; weighing errors are a common source of adverse outcomes. Volumetric dosing reduces risk when working at this scale. - DOET has a slow come-up (often 1–3 h); early redosing is a frequent mistake that can produce unexpectedly intense, prolonged effects. - Expect long stimulation and insomnia; plan 24 hours without obligations and avoid driving/operating machinery until well-rested. - Peripheral vasoconstriction, jaw tension, mild hypertension and anxiety can occur, especially >5 mg and in sensitive users; those with cardiovascular disease should avoid. - On blotter, DOx compounds have historically been mis-sold as LSD; verify with multiple reagents or lab testing, and do not assume blotter equals LSD. - Avoid mixing with MAOIs or lithium; multiple credible case aggregates link lithium+psychedelics to seizures and severe adverse states. - Tramadol and bupropion each lower seizure threshold; avoid combining. - Use an allergy test with any new batch (100–500 μg) due to rarity and uncertain provenance; community reports note variable body load. - Hydrate and eat lightly; avoid overheating. Have a trusted sober sitter for first trials. - DOx insufflation significantly increases risk (rapid spikes, nasal injury); oral is the safer route for titration.

    References

    Data Sources

    Cited References

    Drugs.wiki References

    ← Back to DOET